Mylan on Sept. 8 signed an offer to acquire South African drugmaker Aspen Pharmacares apoplexy organization in Europe for $757 million.
Mylan will pay Aspen $311 million upfront in money and plans to make a final deferred payment of $447 million on June 25, 2021. The sale is expected to close prior to the end of 2020.
© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this content? View our policies by clicking here.
The Canonsburg, Pa.-based drugmaker will get rights for Aspens injectable anticoagulants sold in Europe under the brand names Arixtra, Fraxiparine, Mono-Embolex and Orgaran. These treatments produced nearly $273 million in combined net sales during the 12 months that ended June 30..
Katie Adams –
Wednesday, September 9th, 2020
More articles on pharmacy: Science will come 1st in race for coronavirus vaccine, 9 significant drugmakers pledgeDrug, device companies payments to teaching healthcare facilities might stimulate conflict of interest, study suggestsAstraZeneca halts COVID-19 vaccine trial after unfavorable response in UK patient.
” The acquisition of this apoplexy portfolio is a considerable addition to Mylans European company that will not only make Mylan the 2nd largest supplier of these items to patients in Europe, according to IQVIA, but also strengthen our existing industrial infrastructure to even more broaden access to intricate injectables,” Mylan President Rajiv Malik stated in a news release. “By contributing to our extremely experienced sales and marketing team, we will even more strengthen our current reach in healthcare facilities and enhance the future development of our biosimilars franchise in Europe.”.